Page 2,327«..1020..2,3262,3272,3282,329..2,3402,350..»

Vitamin C helps control gene activity in stem cells

Posted: July 3, 2013 at 1:47 am

July 1, 2013 Vitamin C affects whether genes are switched on or off inside mouse stem cells, and may thereby play a previously unknown and fundamental role in helping to guide normal development in mice, humans and other animals, a scientific team led by UC San Francisco researchers has discovered.

The researchers found that vitamin C assists enzymes that play a crucial role in releasing the brakes that keep certain genes from becoming activated in the embryo soon after fertilization, when egg and sperm fuse.

The discovery might eventually lead to the use of vitamin C to improve results of in vitro fertilization, in which early embryos now are typically grown without the vitamin, and also to treat cancer, in which tumor cells abnormally engage or release these brakes on gene activation, the researchers concluded in a study published June 30, 2013 in the journal Nature.

In the near term, stem-cell scientists may begin incorporating vitamin C more systematically into their procedures for growing the most healthy and useful stem cells, according to UCSF stem-cell scientist Miguel Ramalho-Santos, PhD, who led the study. In fact, the unanticipated discovery emerged from an effort to compare different formulations of the growth medium, a kind of nutrient broth used to grow mouse embryonic stem cells in the lab.

Rather than building on any previous body of scientific work, the identification of the link between vitamin C and the activation of genes that should be turned on in early development was serendipitous, Ramalho-Santos said. "We bumped into this result," he said.

Working in Ramalho-Santos' lab, graduate student Kathryn Blaschke and postdoctoral fellow Kevin Ebata, PhD, were comparing different commercial growth media for mouse stem cells. The researchers began exploring how certain ingredients altered gene activity within the stem cells. Eventually they discovered that adding vitamin C led to increased activity of key enzymes that release the brakes that can prevent activation of an array of genes.

The brakes on gene activation that vitamin C helps release are molecules called methyl groups. These methyl groups are added to DNA at specific points along the genome to prevent specific genes from getting turned on.

During the development of multicellular organisms, humans among them, different patterns of methylation arise in different cells as methyl groups are biochemically attached to DNA at specific points along the genome during successive cell divisions. Normally this gradual methylation, a key part of the developmental program, is not reversible.

But after fertilization and during early development, a class of enzymes called "Tet" acts on a wide array of the methyl groups on the DNA to remove these brakes, so that genes can be activated as needed.

The UCSF researchers demonstrated that Tet enzymes require vitamin C for optimal activity as they act to remove the methyl groups from the DNA and to stimulate gene activity that more faithfully mimics in cultured stem cells what occurs at early stages of development in the mouse embryo.

Read the original here:
Vitamin C helps control gene activity in stem cells

Posted in Stem Cells | Comments Off on Vitamin C helps control gene activity in stem cells

Genome Institute of Singapore Scientists Discover Molecular Communication Network in Human Stem Cells

Posted: July 3, 2013 at 1:47 am

Singapore, July 2, 2013 - (ACN Newswire) - Scientists at A*STAR's Genome Institute of Singapore (GIS) and the Max Planck Institute for Molecular Genetics (MPIMG) in Berlin (Germany) have discovered a molecular network in human embryonic stem cells (hESCs) that integrates cell communication signals to keep the cell in its stem cell state. These findings were reported in the June 2013 issue of Molecular Cell.

Human embryonic stem cells have the remarkable property that they can form all human cell types. Scientists around the world study these cells to be able to use them for medical applications in the future. Many factors are required for stem cells to keep their special state, amongst others the use of cell communication pathways.

Cell communication is of key importance in multicellular organisms. For example, the coordinated development of tissues in the embryo to become any specific organ requires that cells receive signals and respond accordingly. If there are errors in the signals, the cell will respond differently, possibly leading to diseases such as cancer. The communication signals which are used in hESCs activate a chain of reactions (called the extracellular regulated kinase (ERK) pathway) within each cell, causing the cell to respond by activating genetic information.

Scientists at the GIS and MPIMG studied which genetic information is activated in the cell, and thereby discovered a network for molecular communication in hESCs. They mapped the kinase interactions across the entire genome, and discovered that ERK2, a protein that belongs to the ERK signaling family, targets important sites such as non-coding genes and histones, cell cycle, metabolism and also stem cell-specific genes.

The ERK signaling pathway involves an additional protein, ELK1 which interacts with ERK2 to activate the genetic information. Interestingly, the team also discovered that ELK1 has a second, totally opposite function. At genomic sites which are not targeted by ERK signaling, ELK1 silences genetic information, thereby keeping the cell in its undifferentiated state. The authors propose a model that integrates this bi-directional control to keep the cell in the stem cell state.

These findings are particularly relevant for stem cell research, but they might also help research in other related fields.

First author Dr Jonathan Goke from Stem Cell and Developmental Biology at the GIS said, "The ERK signaling pathway has been known for many years, but this is the first time we are able to see the full spectrum of the response in the genome of stem cells. We have found many biological processes that are associated with this signaling pathway, but we also found new and unexpected patterns such as this dual mode of ELK1. It will be interesting to see how this communication network changes in other cells, tissues, or in disease."

"A remarkable feature of this study is, how the information was extracted by computational means from the experimental data," said Prof Martin Vingron from MPIMG and co-author of this study.

Prof Ng Huck Hui added, "This is an important study because it describes the cell's signaling networks and its integration into the general regulatory network. Understanding the biology of embryonic stem cells is a first step to understanding the capabilities and caveats of stem cells in future medical applications."

Notes to the Editor:

See the article here:
Genome Institute of Singapore Scientists Discover Molecular Communication Network in Human Stem Cells

Posted in Stem Cells | Comments Off on Genome Institute of Singapore Scientists Discover Molecular Communication Network in Human Stem Cells

Vitamin C Influences Gene Activity In Stem Cells

Posted: July 3, 2013 at 1:47 am

Featured Article Academic Journal Main Category: Stem Cell Research Also Included In: Nutrition / Diet;Fertility;Cancer / Oncology Article Date: 02 Jul 2013 - 3:00 PDT

Current ratings for: Vitamin C Influences Gene Activity In Stem Cells

5 (3 votes)

5 (1 votes)

Senior author and stem-cell scientist Miguel Ramalho-Santos of the University of California San Francisco (UCSF) and colleagues write about their findings in a June 30th online issue of Nature. In cells, not all genes are active all the time. There is a regulated pattern of gene expression that switches genes on and off. This is held in the epigenome, the set of instructions that get passed on with DNA about how to control the DNA.

One of the mechanisms the epigenome uses to regulate gene expression is DNA methylation. In DNA methylation, the epigenome adds a methyl group to a selected point on the genome to stop certain genes from being expressed.

What Ramalho-Santos and colleagues discovered is that vitamin C plays a crucial role in helping to release the brakes that stop certain genes from being expressed in stem cells in embryos soon after fertilization when the sperm fuses with the egg.

The team came across the result while comparing different types of nutrient for growing mouse embryonic stem cells in the lab.

In a statement, Ramalho-Santos explains that they didn't set out to find what they discovered, "We bumped into this result," he adds.

He and his colleagues wanted to find out how different ingredients in the growth medium affected gene activity in the stem cells. They found adding vitamin C increased the enzyme activity that releases the brakes that normally hold back certain gene expressions.

Read more from the original source:
Vitamin C Influences Gene Activity In Stem Cells

Posted in Stem Cells | Comments Off on Vitamin C Influences Gene Activity In Stem Cells

Scientists discover molecular communication network in human stem cells

Posted: July 3, 2013 at 1:47 am

July 2, 2013 Scientists at A*STAR's Genome Institute of Singapore (GIS) and the Max Planck Institute for Molecular Genetics (MPIMG) in Berlin (Germany) have discovered a molecular network in human embryonic stem cells (hESCs) that integrates cell communication signals to keep the cell in its stem cell state. These findings were reported in the June 2013 issue of Molecular Cell.

Human embryonic stem cells have the remarkable property that they can form all human cell types. Scientists around the world study these cells to be able to use them for medical applications in the future. Many factors are required for stem cells to keep their special state, amongst others the use of cell communication pathways.

Cell communication is of key importance in multicellular organisms. For example, the coordinated development of tissues in the embryo to become any specific organ requires that cells receive signals and respond accordingly. If there are errors in the signals, the cell will respond differently, possibly leading to diseases such as cancer. The communication signals which are used in hESCs activate a chain of reactions (called the extracellular regulated kinase (ERK) pathway) within each cell, causing the cell to respond by activating genetic information.

Scientists at the GIS and MPIMG studied which genetic information is activated in the cell, and thereby discovered a network for molecular communication in hESCs. They mapped the kinase interactions across the entire genome, and discovered that ERK2, a protein that belongs to the ERK signaling family, targets important sites such as non-coding genes and histones, cell cycle, metabolism and also stem cell-specific genes.

The ERK signaling pathway involves an additional protein, ELK1 which interacts with ERK2 to activate the genetic information. Interestingly, the team also discovered that ELK1 has a second, totally opposite function. At genomic sites which are not targeted by ERK signaling, ELK1 silences genetic information, thereby keeping the cell in its undifferentiated state. The authors propose a model that integrates this bi-directional control to keep the cell in the stem cell state.

These findings are particularly relevant for stem cell research, but they might also help research in other related fields.

First author Dr Jonathan Gke from Stem Cell and Developmental Biology at the GIS said, "The ERK signaling pathway has been known for many years, but this is the first time we are able to see the full spectrum of the response in the genome of stem cells. We have found many biological processes that are associated with this signaling pathway, but we also found new and unexpected patterns such as this dual mode of ELK1. It will be interesting to see how this communication network changes in other cells, tissues, or in disease."

"A remarkable feature of this study is, how the information was extracted by computational means from the experimental data," said Prof Martin Vingron from MPIMG and co-author of this study.

Prof Ng Huck Hui added, "This is an important study because it describes the cell's signaling networks and its integration into the general regulatory network. Understanding the biology of embryonic stem cells is a first step to understanding the capabilities and caveats of stem cells in future medical applications."

See the rest here:
Scientists discover molecular communication network in human stem cells

Posted in Stem Cells | Comments Off on Scientists discover molecular communication network in human stem cells

Stem Cells Heal Hearts

Posted: July 3, 2013 at 1:47 am

MINNEAPOLIS, Minn.

About 5.8 million Americans have heart failure, a condition that occurs when the heart can no longer pump enough blood to meet the bodys needs. Now, researchers say a special type of stem cell may be the key to repairing these hearts.

Golf has always been a big part of Ron Signorellis life.

I started when I was ten, Ron told Ivanhoe.

However, Rons congestive heart failure was keeping him away from his favorite pastime.

I was in the hospital over 20 times, Ron said.

Rons heart pumped only 15 percent of blood. He needed help fast.

Theres a large number of patients out there that are really in this situation where theyre gone past what normal medical therapy can do, but yet theyre not sick enough or dont qualify for a heart transplant, Timothy D. Henry, MD, Director of Research Minneapolis Heart Institute Foundation, told Ivanhoe.

Now, a new approach can help patients like Ron. First, doctors extract bone marrow stem cells from the patient. Then, they grow the cells to enhance their healing ability. Those cells are then injected directly into the patients heart.

Our hopes are we improve the quality of their life, as well as the length of their life, Dr. Henry said.

Originally posted here:
Stem Cells Heal Hearts

Posted in Stem Cells | Comments Off on Stem Cells Heal Hearts

Scientists aim to regrow teeth using stem cells- How 3D printing can build new bones

Posted: July 3, 2013 at 1:47 am

Could the days of the root canal, for decades the symbol of the most excruciating kind of minor surgery, finally be numbered?

Scientists have made advances in treating tooth decay that they hope will let them restore tooth tissueand avoid the painful dental procedure. Several recent studies have demonstrated in animals that procedures involving tooth stem cells appear to regrow the critical, living tooth tissue known as pulp.

Treatments that prompt the body to regrow its own tissues and organs are known broadly as regenerative medicine. There is significant interest in figuring out how to implement this knowledge to help the many people with cavities and disease that lead to tooth loss.

In the U.S., half of kids have had at least one cavity by the time they are 15 years old and a quarter of adults over the age of 65 have lost all of their teeth, according to the Centers for Disease Control and Prevention. An estimated $108 billion was spent on dental services in 2010, including elective and out-of-pocket care, according to the CDC.

Tooth decay arises when bacteria or infections overwhelm a tooth's natural repair process. If the culprit isn't reduced or eliminated, the damage can continue. If it erodes the hard, outer enamel and penetrates down inside the tooth, the infection eventually can kill the soft pulp tissue inside, prompting the need for either a root canal or removal of the tooth. Pulp is necessary to detecting sensation, including heat, cold and pressure, and contains the stem cellsundifferentiated cells that turn into specialized onesthat can regenerate tooth tissue.

Researchers from South Korea and Japan to the U.S. and United Kingdom have been working on how to coax stem cells into regenerating pulp. The process is still in its early stages, but if successful, it could mean a reduction or even elimination of the need for painful root canals.

While much of the work has shown promise in the lab and in early work in animals, including dogs, there have only been a few reports of experiments in humans.

The root-canal procedure involves cleaning out the infected and dead tissue in the root canal of the tooth, disinfecting the area and adding an impermeable seal to try to prevent further infection.

But the seal does not always prevent new infection. While the affected tooth remains in the mouth, it is essentially dead, which could impact functions like chewing. That also means no living nerves remain in the tooth to detect further decay or infection. Infection could subsequently spread to surrounding tissue without detection. An estimated 15.1 million root canals are performed in the U.S. annually, according to a 2005-06 survey by the American Dental Association, the most recent data available.

"The whole concept of going for pulp regeneration is that you will try and retain a vital tooth, a tooth that is alive," says Tony Smith, a professor in oral biology at the University of Birmingham in the U.K. "That means the tooth's natural defense mechanisms will still be there.

Read more:
Scientists aim to regrow teeth using stem cells- How 3D printing can build new bones

Posted in Stem Cells | Comments Off on Scientists aim to regrow teeth using stem cells- How 3D printing can build new bones

ResearchMoz.us: Stem Cells Market (Adult, Human Embryonic, Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell …

Posted: July 3, 2013 at 1:47 am

ALBANY, New York, July 1, 2013 /PRNewswire/ --

New Report Added in ResearchMoz Reports Database Stem Cells Market (Adult, Human Embryonic, Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell Production, Cell Acquisition, Expansion, Sub-Culture) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012-2018

ResearchMoz announces that it has published a new study Stem Cells Market (Adult, Human Embryonic, Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell Production, Cell Acquisition, Expansion, Sub-Culture)

Stem cells are undifferentiated cells which are capable of differentiating into any type of cell that make-up the human body and thus, are capable of producing non-regenerative cells such as neural and myocardial cells. This report estimates the market for global stem cells in terms of revenue (USD billion) for the period 2012 - 2018, keeping 2011 as the base year. The global stem cells market is mainly segmented into four major sub-types namely market by products, market by technology, market by applications and market by geography.

To Browse Full TOC, Tables & Figures visit:http://www.researchmoz.us/stem-cells-market-adult-human-embryonic-induced-pluripotent-rat-neural-umbilical-cord-cell-production-cell-acquisition-expansion-sub-culture-global-industry-analysis-size-share-growth-trends-and-forecast-2012-2018-report.html

The market by products is segmented into three sub-types, namely adult stem cells, human embryonic stem cells and other type of stem cells. Adult stem cells are further segmented into hematopoietic stem cells, mesenchymal stem cells, neuronal stem cells, dental stem cells and umbilical cord stem cells. The other types of stem cells include induced pluripotent stem cells, natural rosette cells and very small embryonic like stem cells.

The global stem cells market by technology is segmented into four sub-types, namely cell acquisition, cell production, cryopreservation and expansion and sub-culture. Cell acquisition is further segmented into three sub-types, namely bone marrow harvest, apheresis and umbilical cord blood. Cell production is further segmented into therapeutic cloning, in vitro fertilization, isolation and cell culture.

Latest Reports

Technical Textiles Market

Bitumen Market

Go here to read the rest:
ResearchMoz.us: Stem Cells Market (Adult, Human Embryonic, Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell ...

Posted in Stem Cells | Comments Off on ResearchMoz.us: Stem Cells Market (Adult, Human Embryonic, Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell …

Research and Markets: Stem Cells Market – Global Industry Analysis: 2012 – 2018 Report Highlights the Market Shares of …

Posted: July 3, 2013 at 1:47 am

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/9ccw77/stem_cells_market) has announced the addition of the "Stem Cells Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018" report to their offering.

Stem cells are undifferentiated cells which are capable of differentiating into any type of cell that make-up the human body and thus, are capable of producing non-regenerative cells such as neural and myocardial cells. This report estimates the market for global stem cells in terms of revenue (USD billion) for the period 2012 - 2018, keeping 2011 as the base year. The global stem cells market is mainly segmented into four major sub-types namely market by products, market by technology, market by applications and market by geography.

The global stem cells market by technology is segmented into four sub-types, namely cell acquisition, cell production, cryopreservation and expansion and sub-culture. Cell acquisition is further segmented into three sub-types, namely bone marrow harvest, apheresis and umbilical cord blood. Cell production is further segmented into therapeutic cloning, in vitro fertilization, isolation and cell culture.

The global stem cells market by application is segmented into regenerative medicines and drug discovery and development. Regenerative medicines are further segmented into ten sub-types, namely neurological disorders, orthopedics, cancer, hematological disorders, cardiovascular diseases, injuries, diabetes, liver disorders, incontinence and other disorders like Crohn's disease, infertility, immunodeficiency disorders and organ transplants.

The global stem cells market is also segmented on the basis of geography into North America, Europe, Asia and rest of the world (RoW) regions and the market in terms of USD billion is provided in this report.

Companies Mentioned

- Advanced Cell Technology

- Angel Biotechnology

- Bioheart

Read more:
Research and Markets: Stem Cells Market - Global Industry Analysis: 2012 - 2018 Report Highlights the Market Shares of ...

Posted in Stem Cells | Comments Off on Research and Markets: Stem Cells Market – Global Industry Analysis: 2012 – 2018 Report Highlights the Market Shares of …

Regenerative Medicines: Bone and Joint Applications

Posted: July 3, 2013 at 1:47 am

NEW YORK, July 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Regenerative Medicines: Bone and Joint Applications http://www.reportlinker.com/p0157460/Regenerative-Medicines-Bone-and-Joint-Applications.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation

INTRODUCTION

Regenerative medicine in orthopedic applications is a $2.7 billion per year niche sector in America's $2.6 trillion per year healthcare system. However, it is a sector of immense interest in terms of technical and medical possibilities. The best analogy to the current state of regenerative therapies in the bone and joint healing sector is the nascency of the microprocessors business back in 1971. At that time, microprocessors (namely Intel's 4004), and related innovations, were just an infinitesimal segment of electronic component sales, but this innovation came to dominate the economy. The regenerative therapies sector, particularly areas such as cell therapy and stem cell derived products is in a comparable position today.

The regenerative medicine industry has been in existence for nearly 25 years. Actual product sales, along with research and development (R&D) expenditures, are projected to amount to approximately $2.7 billion in economic activity in 2013, of which venture capital and R&D funding accounts for about $145 million. The rapid evolution of this business is evidenced by the industry consolidation that has occurred since the first edition of this BCC Research report was published in 2003 and even since the most recent edition in 2009. Innumerable buyouts, consolidations, product abandonments, new firms and a few bankruptcies, too, have occurred in just the last several years. These changes are reflected in the Company Profiles section of this report. In addition, intensive R&D efforts at universities, the National Institutes of Health, the National Science Foundation and at FDA centers that focus on cuttingedge technology underscore the importance of this industry.

Regenerative therapies have the potential to improve medical outcomes, enhance quality of life, and reduce overall healthcare costs. A key objective is the utilization of living cells to repair or replace body tissue damaged by injury, disease, or the aging process. The most successful products have drawn upon multidisciplinary fields such as biology, medicine, engineering, and, particularly, biomedical engineering.

The principal focus in this report is on bone and joint applications; however, other regenerative applications such as dental, neurologic, organ regeneration, cardiovascular, urologic, diabetes, and wound care are important and are briefly covered to underscore the larger importance of regenerative therapies. Stemcell research is an important component of the sector as well. For example, the successful differentiation of embryonic stem cells into specific cell types is widely sought as a means to treat traumatic spinalcord injury, as well as diseases such as diabetes, Duchenne muscular dystrophy, heart disease, and vision and hearing loss.

OBJECTIVES AND GOALS OF STUDY

This report focuses on the bone and jointrelated applications of and markets for the various categories of regenerative medicine products currently available and projected to be introduced during the fiveyear forecast period from 2013 through 2018. Market drivers discussed include the status of R&D and what is likely to issue from R&D in the way of actual products and therapies. Other market drivers include the incidence, and rate of growth, of diseases and disorders that will benefit from these products, primarily arthritis, osteoporosis, and various types of bone and joint trauma (e.g., hip fractures, knee injuries); increasing use of nonautograft products by physicians; and innovative devices that incorporate bone and cartilagegrowthstimulating agents in a regenerative appliance. Products discussed include bone and cartilage grafting and regenerative products derived from autologous, allogeneic, and synthetic sources, as well as electrical stimulators for bone growth and regenerative cartilage products.

Profiles are provided of leading and emerging companies in the bone and joint regenerative medicine markets, along with analyses of the current and future positioning of their products and businesses in this active and rapidly changing market. Developmental and clinical stage companies are well covered.

Go here to read the rest:
Regenerative Medicines: Bone and Joint Applications

Posted in Regenerative Medicine | Comments Off on Regenerative Medicines: Bone and Joint Applications

UCLA Stem Cell Gene Therapy for Sickle Cell Disease Advances Toward Clinical Trials

Posted: July 3, 2013 at 1:44 am

Newswise Researchers at UCLAs Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research have successfully established the foundation for using hematopoietic (blood-producing) stem cells (HSC) from the bone marrow of patients with sickle cell disease (SCD) to treat the disease. The study was led by Dr. Donald Kohn, professor of pediatrics and microbiology, immunology and molecular genetics in the life sciences.

Kohn introduced an anti-sickling gene into the HSC to capitalize on the self-renewing potential of stem cells and create a continual source of healthy red blood cells that do not sickle. The breakthrough gene therapy technique for sickle cell disease is scheduled to begin clinical trials by early 2014. The study was published online ahead of press today in Journal of Clinical Investigation.

Gene Therapy Kohns gene therapy approach using HSC from patients own blood is a revolutionary alternative to current SCD treatments as it creates a self-renewing normal blood cell by inserting a gene that has anti-sickling properties into HSC. This approach also does not rely on the identification of a matched donor, thus avoiding the risk of rejection of donor cells. The anti-sickling HSC will be transplanted back into the patients bone marrow and multiplies the corrected cells that make red blood cells without sickling.

The results demonstrate that our technique of lentiviral transduction is capable of efficient transfer and consistent expression of an effective anti-sickling beta-globin gene in human SCD bone marrow progenitor cells, which improved the physiologic parameters of the resulting red blood cells. Kohn said.

Kohn and colleagues found that in the laboratory the HSC produced new non-sickled blood cells at a rate sufficient for significant clinical improvement for patients. The new blood cells survive longer than sickled cells, which could also improve treatment outcomes. The success of this technique will allow Kohn to begin clinical trials in patients with SCD by early next year.

Sickle Cell Disease Affecting more than 90,000 patients in the US, SCD mostly affects people of Sub-Saharan African descent. It is caused by an inherited mutation in the beta-globin gene that makes red blood cells change from their normal shape, which is round and pliable (like a plastic bag filled with corn oil), into a rigid sickle-shaped cell (like a corn flake). Normal red blood cells are able to pass easily through the tiniest blood vessels, called capillaries, carrying oxygen to organs such as the lungs, liver and kidneys. But due to their rigid structure, sickled blood cells get stuck in the capillaries and deprive the organs of oxygen, which causes organ dysfunction and failure.

Current treatments include transplanting patients with donor HSC, which is a potential cure for SCD, but due to the serious risks of rejection, only a small number of patients have undergone this procedure and it is usually restricted to children with severe symptoms.

CIRM Disease Team Program This study was supported in part by a Disease Team I Award from the California Institute for Regenerative Medicine (CIRM), the states stem cell research agency created by voter initiative in 2004. The purpose of the disease team program is to support research focused on one particular disease that leads to the filing of an investigational new drug application with the FDA within four years. The program is designed to encourage translational research, which means to take scientific discoveries from the laboratory to the patient bedside as quickly as possible. This requires new levels of collaboration between basic laboratory scientists, medical clinicians, biotechnology experts and pharmacology experts, to name a few.

Other support came from the UCLA Broad Stem Cell Research Center and Jonsson Comprehensive Cancer Center and the Ruth L. Kirschstein National Research Service Award.

The stem cell center was launched in 2005 with a UCLA commitment of $20 million over five years. A $20 million gift from the Eli and Edythe Broad Foundation in 2007 resulted in the renaming of the center. With more than 200 members, the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research is committed to a multi-disciplinary, integrated collaboration of scientific, academic and medical disciplines for the purpose of understanding adult and human embryonic stem cells. The center supports innovation, excellence and the highest ethical standards focused on stem cell research with the intent of facilitating basic scientific inquiry directed towards future clinical applications to treat disease. The center is a collaboration of the David Geffen School of Medicine, UCLAs Jonsson Cancer Center, the Henry Samueli School of Engineering and Applied Science and the UCLA College of Letters and Science. To learn more about the center, visit our web site at http://www.stemcell.ucla.edu

Continue reading here:
UCLA Stem Cell Gene Therapy for Sickle Cell Disease Advances Toward Clinical Trials

Posted in Gene therapy | Comments Off on UCLA Stem Cell Gene Therapy for Sickle Cell Disease Advances Toward Clinical Trials

Page 2,327«..1020..2,3262,3272,3282,329..2,3402,350..»